Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1.

Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo.

Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1.

Popular Novo Nordisk and Eli Lilly drugs are included

For the first time, Medicare will cover GLP-1 drugs prescribed solely for weight loss for eligible beneficiaries at a $50 monthly copay.

The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.

El sistema de salud pública financiará terapias contra la obesidad mediante un programa piloto de 18 meses. Conoce cuándo entra en vigor el beneficio y quiénes califican

The program, which will make weight loss drugs eligible for people on Medicare for $50 a month, is only set to run for 18 months.

Medicare enrollees as of July 1 can get GLP-1s covered by Part D prescription insurance as part of a trial program until the end of 2027.

Some Medicare beneficiaries are getting access to weight loss drugs this month through a so-called Bridge program. But questions remain regarding the pilot and its cost.

For the first time, Medicare will cover GLP-1s for obesity-related weight loss, without any other medical conditions.

Starting Wednesday, millions of Medicare-qualifying adults will have access to popular medications for weight loss at deep discounts through a temporary federal program called the…

The program creates the first obesity-only Medicare coverage pathway

Medicare has started covering obesity drugs for the first time – and companies like Walmart and CVS Health are playing an important role for patients.